The demo obtained the two its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically major and top-quality enhancements in liver fibrosis without worsening of steatohepatitis, as well as resolution of steatohepatitis without having worsening of liver fibrosis in individuals with MASH when compared with placebo.1The next major adve